Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University, Heidelberg, Germany.
J Ocul Pharmacol Ther. 2011 Aug;27(4):401-5. doi: 10.1089/jop.2011.0080.
To assess side differences in patients undergoing bilateral intravitreal bevacizumab injections as treatment of exudative age-related macular degeneration (AMD).
The clinical interventional case series study included 48 patients (96 eyes) who consecutively and bilaterally received 3 intravitreal bevacizumab injections. The mean age was 76.5±7.5 years (range: 59-88 years). Follow-up was 6 months. Main outcome parameters were best-corrected visual acuity (BCVA) and measurements by optic coherence tomography. The eyes of the same patient were assigned to a study group 1 for the eye with the higher visual acuity at baseline, and study group 2 for the contralateral eye with the lower visual acuity at baseline.
The increase in BCVA was significantly (P=0.02) greater in group 2 (0.07±0.25 logarithm of the minimum angle of resolution, LogMAR) than in group 1 (0.05±0.29 LogMAR). The height of a detached retinal pigment epithelium, the height of subretinal fluid, and the tissue thickness of the macula decreased significantly (P<0.05) in group 2 during follow-up, whereas these parameters did not markedly change in the eyes of group 1 (P=0.96, P=0.38, and P=0.07, respectively). The reduction in the height of a detached retinal pigment epithelium and in the height of subretinal fluid was significantly more pronounced in group 2 than in group 1 (P=0.03, P=0.04, respectively).
After an initial set of 3 bilateral bevacizumab injections, patients with bilateral exudative AMD have a higher likelihood for an improvement in vision in the worse-seeing eye at baseline than in the better-seeing eye.
评估接受双侧玻璃体内贝伐单抗注射治疗渗出性年龄相关性黄斑变性（AMD）的患者的侧眼差异。
本临床干预性病例系列研究纳入了 48 名（96 只眼）连续双侧接受 3 次玻璃体内贝伐单抗注射的患者。平均年龄为 76.5±7.5 岁（范围：59-88 岁）。随访时间为 6 个月。主要观察指标为最佳矫正视力（BCVA）和光学相干断层扫描测量值。同一患者的双眼被分配到研究组 1（基线时视力较高的眼）和研究组 2（基线时视力较低的对侧眼）。
组 2（0.07±0.25 最小角分辨对数视力，LogMAR）的 BCVA 增加显著大于组 1（0.05±0.29 LogMAR）（P=0.02）。在随访过程中，组 2 的视网膜色素上皮脱离高度、视网膜下液高度和黄斑组织厚度显著降低（P<0.05），而组 1 的这些参数没有明显变化（P=0.96，P=0.38，P=0.07）。组 2 的视网膜色素上皮脱离高度和视网膜下液高度的降低明显大于组 1（P=0.03，P=0.04）。
在初始的 3 次双侧贝伐单抗注射后，基线时视力较差的眼比视力较好的眼更有可能改善视力。
